drugset / Trial / NCT00003109
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus raltitrexed in treating patients who have refractory solid tumors that have not responded to previous therapy.
Timeline
- Start
- 1997-12
- Primary completion
- 2000-10
- Completion
- 2001-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Raltitrexed | Small molecule | — | Intravenous |